Invectys starts the third dose level of its phase I clinical trial evaluating INVAC-1, an innovative anti-cancer therapeutic vaccine A new clinical hope in cancer…
Invectys raises 1.7 million Euros more to finance the clinical development of its therapeutic cancer vaccine With a total of 10 million euros raised, new premises,…
Invectys Initiates Phase I Clinical Trial Evaluating INVAC-1 Therapeutic Vaccine for Cancer Patients A new clinical hope in cancer immunotherapy Paris, May 12th,…
Invectys receives ANSM approval to start clinical trial for INVAC-1, its leading anticancer immunotherapy INVAC-1 is an anticancer candidate vaccine targeting…
A new clinical hope in cancer immunotherapy Paris, May 12th, 2015 – Invectys announces today that it has initiated a phase I clinical trial of its immunotherapeutic…
Strong antigen-specific T-cell immunity induced by a recombinant human TERT measles virus vaccine and amplified by a DNA/viral vector prime boost in IFNAR/CD46…
